CALLA-positive myeloma: an aggressive subtype with poor survival.
Detailed immunotyping was carried out on 21 direct myeloma bone marrow aspirates and eight human myeloma cell lines. Four previously untreated common acute lymphoblastic leukemia antigen (CALLA)-positive myeloma patients were identified and six of eight cell lines (75%) were also positive. CALLA positivity, as part of an immature B phenotype, was found to correlate with very aggressive clinical disease: median survival six months v 56 months for the CALLA-negative group.
Durie
B G
BG
Grogan
T M
TM
D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000032:analysis*; D005260:Female; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000145:classification / Q000276:immunology* / Q000473:pathology; D015260:Neprilysin; D011379:Prognosis
D000951:Antigens, Neoplasm; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D015260:Neprilysin